Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells
- 1.1k Downloads
Hypoacetylation on histone H3 of human prostate cancer cells has been described. Little is known about the modifications of other histones from prostate cancer cells.
Histones were isolated from the prostate cancer cell line DU-145 and the non-malignant prostatic cell line RC170N/h. Post-translational modifications of histone H2B were determined by liquid chromatography-mass spectrometry (LC-MS)/MS.
The histone H2B of the prostate cancer cell line DU-145 was found to have hypoacetylation, hypomethylation, and dephosphorylation as compared to the non-malignant prostatic cell line RC170N/h. H2B regained acetylation on multiple lysine residues, phosphorylation on Thr19, and methylation on Lys23 and Lys43 in the DU-145 cells after sodium butyrate treatment.
The histone H2B of DU-145 prostate cancer cells are hypoacetylated, hypomethylated, and dephosphorylated. Histone deacetylase inhibitor reversed this phenotype. Epigenetic agent may therefore be useful for prostate cancer therapy and worth further investigation.
KeywordsEpigenomes Histone H2B modifications Mass spectrometry Acetylation Deacetylases Hypoacetylation Prostate cancer
To the editor
Analyses of H2B from RC170N/h cells revealed acetylation at K5, K16, and K20 (Fig. 1b). The methylations were found to be tri-methylated at K15 and K120, di-methylated at K23, and mono-methylated at K116 (Fig. 1b). The same peptides 16KAVTKAQK23 and 17AVTKAQKKDGKK28 that were analyzed for the DU-145 cells, together with other peptides including 1PDPSKSAPAPKKGSKKAVTKAQK23 and 109HAVSEGTKAVTK120, were examined for these modifications. The non-malignant RC170N/h cells clearly had more acetylated and methylated lysine residues on H2B than the DU-145 cancer cells.
To evaluate the histone deacetylase (HDAC) activity, DU-145 cells were treated with sodium butyrate, an inhibitor of HDACs. After butyrate treatment of these cells, acetylation on lysine residues, K5, K11, K12, K16, K20, and K27 of H2B, was identified (Fig. 1c). Specifically, the acetylation changes were detected in the following peptides, 6SAPAPKKGSK15, 16KAVTKAQK23, 1PEPAKSAPAPK11, and 17AVTKAQKKDGKK28. The fact that acetylation on H2B in the DU-145 cells was detected in multiple additional lysine residues after HDAC inhibition by sodium butyrate suggests that there was an excessive HDAC activity in the DU-145 cells. Acetylation of K5, K16, and K20 was also observed in the non-malignant RC170N/h cells (Fig. 1b, c). These data showed that the DU-145 cancer cells had a single K20 acetylation site, compared to the non-malignant RC170N/h cells that had three sites at K5, K16, and K20. The NaB-treated DU-145 cells had six acetylation sites at K5, K11, K12, K16, K20, and K27. The differences in the acetylation sites were detected at the N termini, without involving the alpha helices which start at amino acid residue 37 of H2B (Fig. 1, underscored sequences). The small lung carcinoma cells have six sites at K5, K11, K12, K15, K16, and K20 ; The Jurkat cells have three sites at K12, K15, and K20 , whereas the untreated DU-145 cells in this study have one acetylated K20. These results indicate that there are clear differences in acetylation sites among the human cell lines. These differences constitute the epigenetic signatures of individual neoplastic clones.
There was no obvious phosphorylation detected on histone H2B peptides from the DU-145 prostate cancer cells. However, phosphorylation was detected at serines S6 and S14, as well as threonines T19 and T115 of the H2B histone in the non-malignant prostatic RC170N/h cells (Fig. 1b). Phosphorylation was detected on H2B peptides, 16KAVTKAQK23, 1PDPSKSAPAPKKGSKKAVTKAQK23, and 109HAVSEGTKAVTK120. When the DU-145 cells were treated with sodium butyrate (NaB), phosphorylation was found on threonine T19 (Fig. 1c). The increase in phosphorylation of H2B in DU-145 cells after NaB treatment is particularly intriguing. This provides the first evidence of the possible cross talk of HDACs and serine/threonine kinases.
As illustrated in Fig. 2, we postulate that the abnormal HDAC activity could turn the reversible histone modifications into irreversible, leading to perpetual aberrant epigenomes. An enhanced HDAC activity or a reduced K-acetyltransferase activity would tip the balance towards deacetylation. These could perpetuate the epigenetic changes and result in carcinogenesis. Targeting epigenetic modifications by inhibiting HDACs and DNA methyltransferases has become novel cancer therapies [2, 3, 10, 11, 12]. This study also suggests that HDAC inhibitors may be a potential therapeutic option for prostate cancer.
In conclusion, the histone H2B of DU-145 prostate cancer cells are hypoacetylated, hypomethylated, and dephosphorylated. Histone deacetylase inhibitor reversed this phenotype. Epigenetic agent may therefore be useful for prostate cancer therapy and worth further investigation.
- 4.Wyrick JJ, Parra MA. The role of histone H2A and H2B post-translational modifications in transcription: a genomic perspective. Biochim Biophys Acta. 1789;2009:37–44.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.